Towards end of the video...
The reasons why Sarepta, Pfizer and Roche are spending $$$$$$ on DMD.
Market estimated to be $10 Billion per year by 2030.
$10 Billion reasons to partner with ANP for pivotal Phase IIB.
All we have to do is replicate the successful Phase IIA results.
One 12 month trial away from accelerated approval.
.
Towards end of the video... The reasons why Sarepta, Pfizer and...
Add PER (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
6.4¢ |
Change
-0.010(13.5%) |
Mkt cap ! $57.69M | |||
| Open | High | Low | Value | Volume |
| 7.4¢ | 7.6¢ | 5.9¢ | $516.4K | 8.992M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 2 | 339429 | 6.4¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 7.6¢ | 143169 | 1 |
View Market Depth
| Last trade - 16.10pm 25/04/2024 (20 minute delay) ? |
|
|||||
|
Last
5.9¢ |
Change
-0.010 ( 21.3 %) |
||||
| Open | High | Low | Volume | ||
| 7.6¢ | 7.6¢ | 5.9¢ | 132018 | ||
| Last updated 15.49pm 25/04/2024 ? | |||||
| PER (ASX) Chart |